1 / 12

Facilitating creative partnerships in biopharmaceutical research

Facilitating creative partnerships in biopharmaceutical research. Diane Gosselin , VP Research and Business Development . Ottawa, November 30 th , 2009. The current pharma R&D business model is increasingly unsatisfactory …. 65.2 billion invested in R&D in 2008

talbot
Download Presentation

Facilitating creative partnerships in biopharmaceutical research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Facilitating creative partnerships in biopharmaceutical research Diane Gosselin, VP Research and Business Development Ottawa, November 30th , 2009

  2. The current pharma R&D business model is increasingly unsatisfactory… • 65.2billion invested in R&D in 2008 • Poor innovative product pipelines • Increasing regulatory hurdles • Disillusion from expectations of rapid translation from “genes to drugs” … and requiresto rethink its operational mode and improve productivity • A fostered co-creation of value between academic centers, biotech • companies and the pharmaceutical industry • The possibility to finance creative pre-competitive research with • the potential to impact the whole life science sector • A more flexible management of IP processes • A better way to channel public funds on research agendas • responding to Industry and Regulators needs

  3. Our mission To identify, finance and support innovative research activities, primarily focusing on enabling technologies in drug discovery, fulfilling the innovation needs of the pharmaceutical industry To create a collaborative ground between the academic and private sectors based on trust, creativity and mutual benefit

  4. Founding Partners

  5. A fully mutualized consortium unlike other existing initiatives

  6. Scope of the funding program Promote the development of innovative enabling technologies that can facilitate biopharmaceutical research Not intended to fund the development of specific molecules Must address the most important challenges of the bio-pharmaceutical industry Must generate clear deliverables with immediate applications in the drug discovery or development process Promote creativity and collaborations between public and private organizations (strongly encouraged, but not mandatory)

  7. Funding specifics • Amount and Duration • $1,000,000 - $3,000,000/project (3 years) • Subject to milestone achievement and satisfactory follow-ups • 3-5 projects funded per year • Mentorship • For each project a specific industrial advisory committee ensures that the end-products are well aligned with the needs of the biopharmaceutical research industry • Intellectual property • IP belongs to the inventors and their respective institutions • A non exclusive end-user license option will be granted to the CQDM’s industrial sponsors for internal research purposes only • The owners of IP will maintain the right to exploit or to out-license to third parties

  8. 2008-2009 competition 78 letters of intent 12 full applications 4 selected projects 3 funded projects • A total of $6.0M in funding • Over 70 researchers from 4 universities • and 3 private organizations

  9. Identification of biomarkers for measurement of pancreatic beta cell mass, function and stratification of treatment response patients. Principal investigator Eustache Paramithiotis, CaprionProteomics. Budget : $2.305M Development of new vaccine antigens based on Virus-Like Particles (VLPs). Principal investigator: Louis-Philippe Vézina, Medicago. Budget: $1.775M Multiparametric profiling of G protein-coupled receptor efficacy ligand using multiplexed biosensors: linking signalling signatures to therapeutic efficacy. Principal investigator: Michel Bouvier, Unviersity of Montreal. Budget : $1.827 M 2008-2009 funded projects

  10. 1) Innovative technology platforms2) Translational technologies 3) Cutting edge drug delivery technologies Research agenda (2009-2010) This year, priority will be given to the following enabling technologies:

  11. An innovative consortium • Benefits to Biotech companies and to academic institutions • Additional source of funding • Access to specialized and dedicated resources • Closer links with industrial colleagues • Increased international competiveness • Benefits to Pharma companies • Access to innovation aligned with the needs of the industry • Excellent leverage (>10 fold) for R&D investment dollars • Closer links with the academic and the Biotech sectors • Cooperative interactions with competitors • Closer interactions with government bodies

  12. Corporate development • CQDM is planning to extend its activities through national and international collaborations • CQDM wishes to enter into bilateral agreements with similar organizations in the US and in Europe to finance joint research projects in drug discovery and development • Aligning international research resources with global pharma R&D agendas is likely to impact the productivity of drug discovery in the industry

More Related